Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse

GLASGOW, Scotland—Joseph Mikhael MD, Professor at the Translational Genomics Research Institute (TGen), Phoenix, Arizona USA, talks with Sarah Maxwell at the International Myeloma Society 2026 Annual Meeting about the importance of introducing B-cell maturation antigen-targeted therapies at first relapse for patients with multiple myeloma.